CD147 (soluble) Mouse anti-Human, FITC, Clone: MEM-M6/1, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA119588
This antibody recognizes an epitope in the N-terminal Ig domain (D1) of CD147 (Neurothelin), a 50-60 kDa type I transmembrane glycoprotein primarily expressed on all leukocytes, red blood cells, platelets and endothelial cells; it is not expressed by resting lymphocytes. This is a high-affinity antibody capable of binding to unstimulated peripheral blood T cells.CD147 (basigin, neurothelin, OX-47, 5A11, CE9, M6, EMMPRIN, extracellular matrix metalloproteinase inducer, TCSF, tumour cell-derived collagenase-stimulatory factor) is a 50-60 kDa glycoprotein with multiple glycosylated forms. CD147 is a plasma membrane protein that is important in spermatogenesis, embryo implantation, neural network formation, and tumor progression. CD147 is also a member of the immunoglobulin superfamily. The highest level of CD147 expression is on metabolically active cells, such as lymphoblasts, inflammatory cells, brown adipocytes and maligt tumor cells. CD147 has multiple functions, including facilitating of cell surface expression of monocarboxylate transporter proteins and extracellular matrix metalloproteinases, regulation of integrin functions, it plays roles in cell development and activation, fetal development or retinal function.
|Protein A-CR purified soluble recombit form of CD147, CD147Rg.|
|PBS with 0.2% BSA and 15mM sodium azide|
|5F7, CD147, EMMPRIN, M6, OK, TCSF, CD147 antigen, OK blood group antigen, basigin, collagenase stimulatory factor, extracellular matrix metalloproteinase inducer, leukocyte activation antigen M6, tumor cell-derived collagenase stimulatory factor|
|4° C, store in dark, DO NOT FREEZE!|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok